Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Mallinckrodt
Colorcon
Moodys
McKinsey
Harvard Business School

Last Updated: June 29, 2022

Investigational Drug Information for PLX3397


✉ Email this page to a colleague

« Back to Dashboard

What is the drug development status for PLX3397?

PLX3397 is an investigational drug.

There have been 24 clinical trials for PLX3397. The most recent clinical trial was a Phase 3 trial, which was initiated on October 20th 2020.

The most common disease conditions in clinical trials are Melanoma, Giant Cell Tumors, and Giant Cell Tumor of Tendon Sheath. The leading clinical trial sponsors are Plexxikon, Daiichi Sankyo, Inc., and Daiichi Sankyo Co., Ltd.

There are sixty-three US patents protecting this investigational drug and five hundred and ninety-six international patents.

Recent Clinical Trials for PLX3397
TitleSponsorPhase
A Study of Pexidartinib in Tenosynovial Giant Cell Tumor in JapanDaiichi Sankyo Co., Ltd.Phase 2
Study to Evaluate Discontinuation and Re-Treatment in Participants With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With PexidartinibDaiichi Sankyo, Inc.Phase 4
A Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCTDaiichi Sankyo Co., Ltd.Phase 3

See all PLX3397 clinical trials

Clinical Trial Summary for PLX3397

Top disease conditions for PLX3397
Top clinical trial sponsors for PLX3397

See all PLX3397 clinical trials

US Patents for PLX3397

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
PLX3397 See Plans and Pricing Synthesis of a compound that modulates kinases Plexxikon Inc. (Berkeley, CA) Daiichi Sankyo Company, Limited (Tokyo, JP) See Plans and Pricing
PLX3397 See Plans and Pricing Solid forms of (1S,4S)-4-(2-(((3S,4R)-3-fluorotetrahydro-2H-pyran-4-yl)amino)-8-((2,4,6-- trichlorophenyl)amino)-9H-purin-9-yl)-1-methylcyclohexane-1-carboxamide and methods of their use Signal Pharmaceuticals, LLC (San Diego, CA) See Plans and Pricing
PLX3397 See Plans and Pricing Formulations of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)m- ethyl)-2,2-difluoroacetamide Celgene Corporation (Summit, NJ) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Mallinckrodt
Colorcon
Moodys
McKinsey
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.